Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 27 | 2021Medtronic CY Q1 '21 Earnings Update; FDA Accepts IND for Lilly/Dicerna Cardiometabolic Asset; Dario Digital Therapeutics PublicationPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other May 26 | 2021InPen and Guardian 4 Sensor Receive CE Mark; Oramed Ph3 Oral Insulin Update; Adocia Files Patents for Obesity, NASH, and T2DMPurchase Blast
$599
Posted in: Other May 25 | 2021Provention Bio Teplizumab Adcom Pre-read Materials PostedPurchase Blast
$599
Posted in: Glucagon, Other May 24 | 2021Xeris to Acquire Strongbridge; NGM Bio Discontinues NASH Program; BI Selects NASH Drug Candidate From DicernaPurchase Blast
$599
Posted in: Other May 20 | 2021SURPASS-4 Data Continue to Impress; Arecor and Lilly PartnershipPurchase Blast$599
Posted in: Glucose Monitoring, Other May 19 | 2021Roche Launches Smartphone-controlled Pump; Metronom Enters CGM JV in China; FDA Draft Guidance on T2DM Glycemic Control Devices; Dario Q1 '21 Earnings Update; New Ascensia BGM Portal; Metacrine Ph2 NASH TrialPurchase Blast
$599
Posted in: Other May 18 | 2021Novartis Post-ACC CV Investor Event Highlights; Inclisiran Expected as Class 2 ReviewPurchase Blast
$599
Posted in: Other May 17 | 2021Novo's Ph2 Ziltivekimab Data @ ACC 2021; Sheldon Koenig Takes Over as Esperion CEO; New T1DM Treatment from NeurodonPurchase Blast
$599
Posted in: SGLT2i May 17 | 2021EMPEROR-Reduced, DAPA-CKD, and Vericiguat Opinions?; May 17-20 CHMP AgendaPurchase Blast
$599
Posted in: Bolus Insulin, Glucagon, Glucose Monitoring, Other May 13 | 2021Senseonics, Xeris, Mannkind, and Bayer Q1 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other May 11 | 2021Lilly Obesity Ph2 GGG Tri-agonist Trial; Novo QW Icodec Ph3 T2DM; Sigilon Q1 '21 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery May 10 | 2021Bigfoot Unity Receives 510(k) Clearance; Bayer's FIGARO-DKD Meets Primary Endpoint; Viatris Q1 '21 Earnings Update; Novo Insulin Product Samples RecalledPurchase Blast
$599
Posted in: Insulin Delivery, SGLT2i May 06 | 2021Omnipod 5 Delayed; Insulet and Lexicon Q1 '21 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other May 06 | 2021Lilly Connected Pen Update; Novo Q1 '21 Post-earnings Event; Provention Bio, BD, ICPT, and REGN Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other May 05 | 2021Tandem, Lannett, Esperion, and Ionis Q1 '21 Earnings Updates; Nemaura Receives Order for its Non-invasive CGMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA May 05 | 2021Novo Nordisk Q1 '21 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA May 04 | 2021New Dual GLP-1/GIP RA from Carmot Receives IND; Lilly ESG Strategy Highlights; Pfizer Q1 '21 Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Other May 03 | 2021Zealand Ph3 RTU Dasiglucagon Results Published in Diabetes Care; Genfit Launches NASHnext Diagnostic TestPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
